- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
BDSI Market Currents
more »
-
April 17 BioDelivery Sciences (BDSI) lands patent approval from the USPTO that will extend its protection on BioErodible MucoAdhesive (BEMA) products, BEMA Buprenorphine and BEMA Buprenorphine/Naloxone. As a result of the action, the firm will land a $15M milestone payment from Endo Pharmaceuticals.
1 Comment[Healthcare]
BDSI in Focus
more »
BDSI Related Articles
more »
BDSI News
more »
-
at CNBC.com (Jan 6, 2012)
BDSI Press Releases and Filings
more »
-
PR Newswire (Mon, 7:00AM)
-
PR Newswire (May 10, 2012)
-
PR Newswire (May 9, 2012)
-
PR Newswire (Apr 17, 2012)
-
PR Newswire (Apr 16, 2012)
BDSI Latest Transcript
more »
Currently, there are no transcripts for BDSI.
BDSI Cramer
more »
Currently, there are no Cramer articles on BDSI.
BDSI Instablog posts
more »
BDSI vs. ETF Alternatives
Company Description
We are a specialty pharmaceutical company that is utilizing licensed and owned proprietary drug delivery technologies to develop and commercialize, either on our own or in partnerships with third parties, significant new formulations of proven therapeutics. Utilizing our drug delivery... More
